Home > Cluster Organisations > BIONIAN CLUSTER

BIONIAN CLUSTER

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Sunday, 6 January, 2013
Number of staff in the management team of the cluster organisation : 
6-10
Regions: 
Aττική (Attiki)
Cluster Excellence Label: 
Other
Membership to other networks/partnerships: 
Cluster Management Team: 
NameSurnamePositionTelephoneEmail
Maria
Tsampoula
Cluster Manager
00302106401112
mtsab@biosbbc.org
Nikitas
Skliros
ECCP Responsible Person
00302106401112
nskliros@ici-trials.gr
Languages spoken: 
English
French
Greek
Sectoral and Industrial Focus
Sectoral Industries: 
Biopharmaceuticals
Education and Knowledge Creation
Technology fields: 
Clinical Research, Trials
Medical Research
S3 EU priority areas: 
e-Health (e.g. healthy ageing)
Power generation / renewable sources
Emerging industries: 
Bio-pharmaceuticals
Blue Growth Industries
Composition of the cluster
Total number of members: 
23
Number of SME members: 
11
Number of larger company members: 
5
Number of research organisations/universities/technology centres: 
7
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Name and link of major players: 
NameWebsiteType
National Technical University
University
University of Athens
University
Hellenic Pasteur Institute
Research Organisation
University of Patras
University
University of Ioannina
University
NATIONAL CENTER FOR SCIENTIFIC RESEARCH "DEMOKRITOS"
Research Organisation
Lilly
Larger Company
Merck
Larger Company
Vidavo
SME
Velti
Larger Company
ICI Trials
SME
Athens Information Technology
Research Organisation
Biophylaxis
SME
Jotis
Larger Company
Hellenic Electronic Equipment Quality Assurance Center (HEEQAC)
Larger Company
Cluster Strategy
Mission/Objectives: 

MISSION

The establishment and development of a Greek biotechnology cluster would most likely impact society as a whole as a result of the provision of high quality health services and products both locally and internationally. Bionian Cluster constitutes a recently established health sciences cluster in Greece and SEE. The Cluster has been established within Greece. The Cluster aims to contribute substantially to regional economic development by overcoming the divide between academic research hubs and related stakeholders of the private industry. The scope of the Cluster’s activities target primarily SEE countries, while aspiring to emerge as an important stakeholder in the Middle East/ North African (MENA) region

VISION

The vision of the Bionian Cluster is to bring Greece to the forefront of biotechnology worldwide in two main themes: (a) the Biomedical Sciences, with a focus on applied clinical research, clinical pharmacology and therapeutics, and(b) the Environmental Health Sciences (EHS), with a focus on the reduction of the burden of human illness and disability through a better understanding of the impact of environmental factors and exposures on disease pathogenesis and progression, as well as on general human health.

 

 

  • Membership at the National Biotechnology Committee on ETAK-ESPA Appropriation Funds, 2007-2013 (EU 7th Framework Program), of the General Secretariat in Research and Technology, Ministry of Development (2007 - 2009)
  • Mapping of the National Biomedical Innovation in Greece (up to 2009), along with the Human Capital on relevant sectors in Biotechnology and Biosciences in Greece and the Greek Diaspora
  • Organizing educational and training sessions, scientific conferences, public awareness events, publishing in highly-acclaimed scientific journals and editing two Scientific Journals in the fields of Biotechnology and Life Sciences (Βio, MedReview) from 2006 to date
  • Working in close collaboration with the Hellenic National Contact Point ("Health" and "Food, Agriculture and Fisheries & Biotechnology"), in EU-funded projects on Health and Biotechnology
  • Signing "Memoranda of Understanding" (MoU) between Hellenic and foreign Biotech firms, Clusters and Academic / Research Institutions worldwide, as with China, Egypt, Russia, Saudi Arabia, U.S.A. (National Institutes of Health, N.I.H.), Bulgaria.
  • Establishing and organizing the International Greek Biotechnology Forum (IGBF) in Greece for the last 5 years (2004-2009)
  • Collaborating with the Hellenic Biotechnology Association, for creation of a Biotechnology -- Health Cluster in Greece, by recruiting top ranked Academic and Research Institutions, as well as Technological Organizations to join forces for common objectives
  • Cooperating with the N.I.H. (U.S.A.), to ensure official rights by our Network for unlimited access to 1) NIH educational infrastructure and resources to organize and administer courses and seminars on Research Methodologies, Clinical Pharmacology and Principles in Clinical Research, based on syllabi and educational material currently in use at the N.I.H., leading to official certification, 2) extended privileged access to technology transfer and original patent applications filed at the N.I.H. Patent Office, to fuel our Translational Research machinery.

"Bionian Cluster, the First Health Sciences Cluster in Greece & South - East Europe, is a unique, well balanced concentration of leading businesses, universities, medical research institutes, academic institutions, hospitals and biosciences in Greece and other countries all over the world."

The recent establishment in Greece of the Bionian Cluster, a multinational conglomerate constituted by academic research centers, pharmaceutical companies, and private industry stakeholders, seeks to overcome the vast aforementioned adversities in biotechnology and health sciences related research fields. It is by this means that the Bionian Cluster aspires to develop into an active regional and international stakeholder for the development of innovative health sciences alliances and market-driven smart specialization solutions. The present work aims to detail the key characteristics and implementation challenges faced by the Bionian Cluster, as well as how these may be effectively overcome. Aggressive networking to optimize coordination of multidisciplinary innovation efforts will prime cooperation between leading Greek research institutions, biomedical researchers of the Greek diaspora and private enterprises. It is aspired that the establishment of the Bionian Cluster will contribute to the development of a novel scientific environment and mode of conduct conducive to business-oriented innovation in SEE.

Do you have a formalised strategy?: 
No
Do you have a specific strategy focus that addresses internationalisation ?: 
No
Services
Support services provided: 
Access to the European Internal market
Access to public support (regional/national programmes, innovation vouchers, etc.)
Direct advisory services
Facilitation of cross-sectorial cooperation
Support of technology transfer
Details of support services: 

Education

The Cluster members include a balanced mix of companies, which contribute complementary skills, expertise, products and services towards realizing the cluster vision. Specifically, the cluster members contribute expertise on clinical investigation, drug development, environmental biomarkers, environment health services, environment sensors, biosensors, ICT systems and analytics for bioinformatics and clinical trials management, as well as diagnostic capabilities. The accumulation of excellence and expertise in all these areas is a clear competitive advantage for Bionian Cluster. More specifically, Bionian Academy with its educational platform takes care of the teaching and training reinforcement of innovative specialties and high specialties, using modern teaching methods, which through interactive and experiential paths, transmit knowledge, enhance skills and lead to the perfection and the long life education of the cluster’s members.

Clinical Investigation

Clinical Investigation (CI), with a focus on applied clinical research, clinical pharmacology and therapeutics. The cluster empowers the execution of high quality clinical research operations spanning all phases of drug development, having also as a major priority to include in the near future  clinical investigation associated with biosimilar and generic drugs including clinical trial for drugs targeting niche and/or high-growth markets such as oncology.

Bionian Cluster has the ability to manage the procedures concerning the application for marketing authorization for generics and prototype drugs in the Central and Western Europe. Additionally, we offer practical conduct of all phases of clinical studies (the I-II-III-etc.), bioequivalence studies, environmental residues and veterinary drugs (marketing authorization is included).

Environmental Health Sciences

Environmental Health Sciences (EHS), with a focus on the reduction of the burden of human illness and disability through a better understanding of the impact of environmental factors and exposures on  disease pathogenesis and progression, as well as on general human health.

  1. Health Sciences: Molecular Medicine, Network Medicine, Bioequivalence, Medical Genetics – Gene Therapy, Clinical Investigation – Pharmacology, Immuno-targeted Therapies, Biochemical Diagnostics (Genomics / Proteomics / Metabolomics applications), Clean Environment.
  2. Biotechnologies: Stem Cells – Transplants, Medical Devices, Small Molecule Pharma, Biosensors – Diagnostics.
  3. Information Sciences: Bio-informatics, Biomedical Signal Processing/Imaging, Micro-Array Development.

Bioeconomy / Transfer Technology office

In conjunction with the proclaimed assets of Greek biotechnology organizations (e.g., the availability of professionals of the highest caliber and the presence of a market with strong foundations), the clustering effort will establish Greece as one of the world’s  leading territories for conducting high quality applied clinical research and environmental health studies. The object of intervention of our Technology Transfer Office (Bionian TTO) is to confront and overcome accessibility problems between academic institutions and innovation and market members by providing specialized scientific and business services. These services are designed to facilitate the transfer of biotechnology processes, increasing the volume of trade and reducing the commercialization time of new products.

Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
China
Cyprus
Saudi Arabia
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject Name
H2020
INTERREG
Other

Star-Bio

Promotion
Why should partners choose you for cooperation?: 

The First Life Sciences Cluster in Greece & South East Europe

The BIONIAN Cluster is a unique, well balanced concentration of leading businesses, universities, medical research institutes, hospitals and academic institutions in biosciences in Greece and other countries all over the world. The vision of the cluster is to establish Greece at the forefront of biotechnology worldwide in two main areas, which define the thematic focus of the cluster:

1. Clinical Investigation (CI), with a focus on applied clinical research, clinical pharmacology and therapeutics. The clusterempowers the execution of high quality clinical research operations spanning all phases of drug development, having also as a major priority to include in the near future clinical investigation associated with biosimilar and generic drugs including clinical trials for drugs targeting niche and/or high-growth markets such as oncology.

2. Environmental Health Sciences (EHS), with a focus on the reduction of the burden of human illness and disability through a better understanding of the impact of environmental factors and exposures on disease pathogenesis and progression, as well as on general  human health.

 To realize this vision, BIONIAN capitalises on clustering as a means of creating critical mass for sustainable competitive advantages and for competing globally in the CI/EHS areas. The formation of this critical mass brings together (in close geographical proximity) multi-disciplinary expertise contributed by the cluster members. Specifically, the cluster joins:  authorities in clinical investigation, leading pharmaceutical companies (multinational large enterprises and niche SMEs), prominent enterprise and research laboratories in e-health/bioinformatics, health services providers, as well as environmental health experts. 

BIONIAN introduces a holistic approach to clinical investigation, characterized by: support of clinical studies of all phases, the inclusion of biological/medical/environmental factors, the exploitation of latest advances in ICT, the development of infrastructures/ expertise for CI in various topics/scales/ goals, and alignment to the trend of «personalized medicine».

This holistic approach allows the establishment of BIONIAN as a leading hub in clinical investigation and environment health studies. BIONIAN also gives a significant boost to the development and sales of other products and services of its members, since it  provides an innovation testbed for the development of new products and services that fall within the members’ business activities.